A melanoma skin cancer immunotherapy treatment made from genetically-engineered cells of the herpes simplex virus-1 may be effective for patients both in early and advanced stages of the disease. Results of a phase three clinical trial, published in the Journal of Clinical Oncology, of the experimental drug found cancer didn’t progress in 16.3 percent of the…
(more…)
Alan Colmes is the publisher of Liberaland.
Leave a Reply
You must be logged in to post a comment.